Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis

QJM: An International Journal of Medicine

Volumn 90, Issue 6, 1997, Pages 401-409

  Adu, D ^a,b   Pall, A ^a   Luqmani, R A ^a   Richards, N T ^a   Howie, A J ^a   Emery, P ^a   Michael, J ^a   Savage, C O S ^a   Bacon, P A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POLYARTERITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SYSTEMIC VASCULITIS; TREATMENT FAILURE; WEGENER GRANULOMATOSIS;

EID: 0030993763     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/90.6.401     Document Type: Article

References (23)

1. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic vasculitis. N Engl J Med 1979; 301:235-8.
2. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Clinical Review. Ann Intern Med 1983; 98:76-85.
3. Savage COS, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467-83.
4. Adu D, Howie AJ, Scott DGI, et al. Polyarteritis and the kidney. Q J Med 1987; 62:221-37.
5. Guillevin L, Jarousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. J Rheumatol 1991; 18:567-74.
6. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116:488-98.
7. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993; 86:779-89.
8. Stillwell TJ, Benson RC Jr, De Remee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31:467-70.
9. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in the treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76:377-84.
10. Austin III HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986; 314:614-19.
11. Steppat D, Gross WL. Stage adapted treatment of Wegener's Granulomatosis. Klinische Wochenschrift 1989; 67:666-71.
12. Falk RJ, Hogan S, Carey TS, Jennette C. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990; 113:656-63.
13. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant 1991; 6:531-5.
14. Hoffman GS, Leavitt RY, Fleischer TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89:403-10.
15. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and ANCA titre on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37:919-24.
16. Adu D, Luqmani R, Bacon P. Polyarteritis, Wegener's granulomatosis and Churg-Strauss syndrome. In: Maddison PJ, Isenberg DI, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology, Vol. 2. Oxford, Oxford Medical Publications, 1993:846-59.
17. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-92.
18. Lüdemann J, Utecht B, Gross WL. Detection and quantification of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen. J Immunol Meth 1988; 114:167-74.
19. Lee SS, Adu D, Thompson RA. Anti-myeloperoxidase antibodies in systemic vasculitis. Clin Exp Immunol 1990; 79:41-6.
20. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score in systemic necrotizing vasculitis. Q J Med 1994; 87:671-8.
21. Lie JT. Nomenclature and classification of vasculitis: Plus ca change, plus c'est la meme chose. Arthritis Rheum 1994; 37:181-6.
22. Rasmussen N, Jayne DRW, Abramowicz D, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101(supp 1):29-34.
23. Bacon PA, Moots RJ, Exley A, et al. VITAL assessment of vasculitis. Clin Exp Rheum 1995; 13:275-8.